Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Subtyping of Advanced Clear Cell Renal Cell Carcinoma in RENOTORCH
ChiCTR2500112859Phase 3Not yet recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- Nov 2025
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, single-arm trial of axitinib and toripalimab in clear cell renal cell carcinoma (ccRCC), sponsored by Chinese PLA General Hospital. Primary endpoints: Multi-omics features and Objective response. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
axitinibtoripalimab
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on ChiCTR2500112859.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500112859.